| Merck Serono S.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120115895 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS - The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. The compounds according to Formula (I) are suitable as modulators of CRTH2. The invention provides Spiro derivatives according to Formula (I) and related formulae that are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, and inflammatory dermatoses such as atopic dermatitis, contact hypersensitivity, allergic contact dermatitis, chronic urticaria/chronic idiopathic/autoimmune urticaria, drag-induced exanthems (e.g., toxic epidermal necrolysis or Lyell's syndrome/Stevens-Johnson syndrome/drug hypersensitivity syndrome), photodermatosis or polymorphous light emption (e.g., photoirritant contact dermatitis, photoallergy contact dermatitis, chronic actinic dermatitis), and myositis neurodegenerative disorders such as neuropatic pain and other diseases with an inflammatory component such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD). | 05-10-2012 |
| 20120115869 | TETRAZOLE DERIVATIVES - The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. | 05-10-2012 |
| 20120071460 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS - The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R | 03-22-2012 |
| 20120035226 | OXADIAZOLE DERIVATIVES - The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis. | 02-09-2012 |
| 20120028959 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS - The invention relates to compounds of formula (I) wherein R | 02-02-2012 |
| 20120022109 | OXADIAZOLE DERIVATIVES - The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis. | 01-26-2012 |
| 20120003182 | GENETIC SEVERITY MARKERS IN MULTIPLE SCLEROSIS - The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLT1, 3′ of HIF1AN, within introns of MEGF11. FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13. | 01-05-2012 |
| 20110319410 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS - The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 12-29-2011 |
| 20110319288 | BANK1 RELATED SNPS AND SLE AND/OR MS SUSCEPTIBILITY - The invention relates to a method of genotyping and for predicting the susceptibility for SLE and/or MS by using SNPs related to BANK1 alone or in combination with at least one other SNP. | 12-29-2011 |
| 20110312960 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS - The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 12-22-2011 |
| 20110306636 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS - The present invention provides oxadiazole pyridine derivatives of Formula (I), their use as medicaments and their use for treating multiple sclerosis and other diseases. | 12-15-2011 |
| 20110293564 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other deseases like cancers. | 12-01-2011 |
| 20110288066 | PHENOXY ACETIC ACID DERIVATIVES - The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses. | 11-24-2011 |
| 20110281891 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF - The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. | 11-17-2011 |
| 20110257170 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers. | 10-20-2011 |
| 20110257098 | COMPOSITIONS AND METHODS FOR TREATING GROWTH HORMONE DEFICIENCY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 10-20-2011 |
| 20110230518 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases. | 09-22-2011 |
| 20110189131 | ACTIVE VARIANTS OF THE IL-18 BINDING PROTEIN AND MEDICAL USES THEREOF - The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof. | 08-04-2011 |
| 20110155756 | MEDICATION DISPENSER - A dispenser for the delivery of medication includes:
| 06-30-2011 |
| 20110104752 | Variation of Recombinant Expression Titres By Optimising Bacterial Ribosome Binding Sites - The present invention provides a method for optimising the ribosome binding site of a promoter for the expression of a gene encoding a polypeptide of interest, placed under the control of said promoter. The invention also relates to a vector containing such optimised promoters, a prokaryotic host cell transformed by said vector, as well as a method for producing a recombinant protein of interest. | 05-05-2011 |
| 20110091901 | Vectors and Methods for Screening Cells for High Expression of Protein of Interest (POI) - This invention refers to industrial production of proteins. More particularly, the invention refers to a fusion protein as a novel chimeric selection marker comprising a peptide conferring resistance to an antibiotic, or a fragment, allelic variant, splice variant or mutein thereof, and at least one sequence comprising SEQ ID NO: 1, 2 or 3, preferably for producing a protein of interest (POI). The inventive chimeric selection marker exhibits: (i) a resistance to an antibiotic; and (ii) a fluorescence activity upon binding of a ligand to the sequence comprising SEQ ID NO: 1, 2 or 3. The invention further refers to nucleic acids encoding the inventive fusion protein and to expression vectors, comprising the inventive fusion protein and additionally the protein of interest (POI). Finally, uses of the inventive chimeric selection marker for screening cells for high expression of a protein of interest (POI) are disclosed. | 04-21-2011 |
| 20110091422 | Use of Genetic Markers for Identifying the Response to Interferon Treatment in Multiple Sclerosis Patients - The present invention relates to the use of genetic markers to identify the response to interferon-beta (IFN-beta) treatment in Multiple Sclerosis (MS) patients as well as a method for treating MS patients and kits for genotyping. | 04-21-2011 |
| 20110086843 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 04-14-2011 |
| 20110086057 | OX40R Binding Agents - The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells. | 04-14-2011 |
| 20110071113 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 03-24-2011 |
| 20110067363 | CHILD-RESISTANT MEDICATION CONTAINER - The child-resistant medication container includes:
| 03-24-2011 |
| 20110028509 | Sulfonamides - The invention relates to compounds of formula I | 02-03-2011 |
| 20110015254 | PTPH1 Inhibitors for the Treatment of Alzheimer's Disease - The present invention relates to the use of PTPH1 inhibitors in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. The present invention also relates to a method of identifying compounds useful in the prevention or treatment of Alzheimer's Disease, or a symptom thereof. | 01-20-2011 |
| 20110008839 | Expression Vectors Comprising the MCMV IE2 Promoter - The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein the expression vector does not contain any complete gene of the mCMV. | 01-13-2011 |
| 20100305137 | PIPERAZINE DERIVATIVES AND METHODS OF USE - The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility. | 12-02-2010 |
| 20100305092 | TRIAZOLE OXADIAZOLES DERIVATIVES - The invention relates to compounds of formula I: | 12-02-2010 |
| 20100291028 | USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES - The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation. | 11-18-2010 |
| 20100279307 | Angiogenesis Inhibiting Molecules, Their Selection, Production and Their Use in the Treatment of Cancer - The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules. | 11-04-2010 |
| 20100260746 | Novel Bank1 Splice Variant - The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway. | 10-14-2010 |
| 20100240658 | Oxadiazole Derivatives - The invention relates to compounds of formula I: | 09-23-2010 |
| 20100239529 | PEG-Interferon-Beta Formulations - The invention relates to a liquid pharmaceutical composition comprising a pegylated IFN-β (PEG-IFN-β), an excipient, a surfactant and a buffer wherein said excipient is a polyol, wherein said surfactant is a non-ionic surfactant and wherein said buffer is a sodium acetate buffer. | 09-23-2010 |
| 20100210619 | 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis - The invention relates to compounds of formula (I): | 08-19-2010 |
| 20100203017 | Cladribine Regimen for Treating Multiple Sclerosis - The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible. | 08-12-2010 |
| 20100197681 | Triazolopyridine Compounds and Their Use as Ask Inhibitors - The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation. | 08-05-2010 |
| 20100189684 | USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY - The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred. | 07-29-2010 |
| 20100184090 | Method for Generating Stable Cell Lines Expressing High Levels of a Protein of Interest - This invention relates to industrial production of proteins. More specifically, the invention relates to a method for obtaining cells that stably express a protein of interest, even when cultivated in the absence of selective pressure. DHFR is used as a surrogate marker. The transfected cells are not selected based on resistance to a toxic compound, but based on fluorescence as measured by FACS using fluorescent MTX. | 07-22-2010 |
| 20100167298 | PURO-DHFR Quadrifunctional Marker and its use in Protein Production - This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR). | 07-01-2010 |
| 20100137308 | Quinoxaline Compounds and Use Thereof - The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 06-03-2010 |
| 20100136628 | Novel OX40R Binding Agents - The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells. | 06-03-2010 |
| 20100121057 | Process for the Preparation of Piperazine Benzothiazoles - The present invention discloses a process for the preparation of compounds of formula (I) | 05-13-2010 |
| 20100063257 | Purification of FC-TACI Fusion Proteins Using the Oilbody Technology - The invention relates to a process for the purification of Fe-fusion proteins such as TACI-Fc using genetically engineered oilbodies expressing protein A. | 03-11-2010 |
| 20100022757 | Process for the Purification of FC-Containing Proteins - The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. | 01-28-2010 |
| 20090275518 | G-CSF POLYPEPTIDES AND USES THEREOF - The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 11-05-2009 |
| 20090275517 | G-CSF POLYPEPTIDES AND USES THEREOF - The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample. | 11-05-2009 |
